Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7089387 | 0.85 | PTGS2 (0.48) | PTGS2PTGS1PTGER3 | |
| SCHEMBL7085156 | 0.84 | TAAR1 (0.58) | PTGS2PTGS1TAAR1 | |
| SCHEMBL7090583 | 0.82 | PTGS2 (0.53) | PTGS2 | |
| SCHEMBL6728065 | 0.81 | PTGS2 (0.73) | PTGS2PTGS1 | |
| SCHEMBL7087905 | 0.80 | PTGS2 (0.46) | PTGS2PTGS1HTR2AHTR2C | |
| SCHEMBL5723692 | 0.78 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL7085561 | 0.78 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL7084451 | 0.75 | FFAR1 (0.44) | PTGS2PTGS1 | |
| SCHEMBL9288060 | 0.74 | ALOX5AP (0.46) | PTGER3TAAR1 | |
| SCHEMBL31708384 | 0.74 | ALOX5AP (0.46) | PTGER3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | PTGS2 122/4885PTGS1 114/4885HTR2A 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.